LY6E

Across TCGA pan-cancer cohorts, LY6E Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LY6E data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LY6E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6E expression acts as an unfavorable survival marker.

CESC and UCEC are the cancer types where LY6E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	30	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LY6E–CESC (DFS)

Open the CESC breakdown →